sonepcizumab
mAbexperimental
Sphingosine-1-phosphate (S1P) is a signaling sphingolipid, also known as lysosphingolipid. It is also referred to as a bioactive lipid mediator. Sphingolipids at large form a class of lipids characterized by a particular aliphatic aminoalcohol, which is sphingosine. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00661414)
Timeline
Indications
Mechanism of action
- Sphingosine 1-phosphateINHIBITOR
Sphingosine 1-phosphate inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSphingosine-1-phosphate ↗
- ChEMBLCHEMBL2109570 ↗
Also known as
- isonep
- sonepcizumab
- sonepcizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01762033 | Phase 2 | Feb 1, 2013 | Lpath, Inc. |
| NCT01414153 | Phase 2 | Aug 1, 2012 | Lpath, Inc. |
| NCT01334255 | Phase 1 | Mar 1, 2011 | Lpath, Inc., Pfizer |
| NCT00767949 | Phase 1 | Oct 1, 2008 | Lpath, Inc. |
| NCT00661414 | Phase 1 | Apr 1, 2008 | Lpath, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lpath, Inc. | For profit | 5 | 5 | 2 | 2008 |
| Pfizer | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1